Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1017471

Minireview: are SGLT2 inhibitors heart savers in diabetes?


Grubić Rotkvić, Petra; Cigrovski Berković, Maja; Bulj, Nikola; Rotkvić, Luka
Minireview: are SGLT2 inhibitors heart savers in diabetes? // Heart failure reviews, 24 (2019), 1-7 doi:10.1007/s10741-019-09849-3 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1017471 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Minireview: are SGLT2 inhibitors heart savers in diabetes?

Autori
Grubić Rotkvić, Petra ; Cigrovski Berković, Maja ; Bulj, Nikola ; Rotkvić, Luka

Izvornik
Heart failure reviews (1382-4147) 24 (2019); 1-7

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Biomarkers ; Diabetes ; Diabetic cardiomyopathy ; Echocardiography ; SGLT2 inhibitors

Sažetak
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs that promote urinary glucose excretion in the treatment of diabetes, have provoked large interest of scientific and professional community due to their positive and, somehow, unexpected results in the three major cardiovascular outcome trials (EMPA-REG OUTCOME trial with empagliflozin, CANVAS Program with canagliflozin, and DECLARE-TIMI 58 with dapagliflozin). In fact, along with the reduction of major adverse cardiovascular events, SGLT2 inhibitors reduced significantly hospitalization for heart failure regardless of existing atherosclerotic cardiovascular disease or a history of heart failure. The latter have reminded us of the frequent but neglected entity of diabetic cardiomyopathy which is currently poorly understood despite its great clinical importance. Physiological mechanisms responsible for the benefits of SGLT2 inhibitors are complex and multifactorial and still not well defined. Interestingly, the time frame of their effect excludes a glucose- and antiatherosclerotic-mediated effect. It would be of great importance to better understand SGLT2 inhibitor mechanisms of action since they could have a potential to be used in early stages of diabetes as cardioprotective agents. There are widely available biomarkers as well as echocardiography that are used in everyday clinical practice and could elucidate physiological mechanisms in the heart protection with SGLT2 inhibitors treatment but studies are still lacking. The purpose of this minireview is to summarize the latest concepts about SGLT2 inhibitors and its benefits regarding diabetic cardiomyopathy especially on its early stage development and to discuss controversies and potential future developments in the field.

Izvorni jezik
Engleski



POVEZANOST RADA


Profili:

Avatar Url Maja Cigrovski Berković (autor)

Avatar Url Nikola Bulj (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Grubić Rotkvić, Petra; Cigrovski Berković, Maja; Bulj, Nikola; Rotkvić, Luka
Minireview: are SGLT2 inhibitors heart savers in diabetes? // Heart failure reviews, 24 (2019), 1-7 doi:10.1007/s10741-019-09849-3 (međunarodna recenzija, članak, znanstveni)
Grubić Rotkvić, P., Cigrovski Berković, M., Bulj, N. & Rotkvić, L. (2019) Minireview: are SGLT2 inhibitors heart savers in diabetes?. Heart failure reviews, 24, 1-7 doi:10.1007/s10741-019-09849-3.
@article{article, author = {Grubi\'{c} Rotkvi\'{c}, Petra and Cigrovski Berkovi\'{c}, Maja and Bulj, Nikola and Rotkvi\'{c}, Luka}, year = {2019}, pages = {1-7}, DOI = {10.1007/s10741-019-09849-3}, keywords = {Biomarkers, Diabetes, Diabetic cardiomyopathy, Echocardiography, SGLT2 inhibitors}, journal = {Heart failure reviews}, doi = {10.1007/s10741-019-09849-3}, volume = {24}, issn = {1382-4147}, title = {Minireview: are SGLT2 inhibitors heart savers in diabetes?}, keyword = {Biomarkers, Diabetes, Diabetic cardiomyopathy, Echocardiography, SGLT2 inhibitors} }
@article{article, author = {Grubi\'{c} Rotkvi\'{c}, Petra and Cigrovski Berkovi\'{c}, Maja and Bulj, Nikola and Rotkvi\'{c}, Luka}, year = {2019}, pages = {1-7}, DOI = {10.1007/s10741-019-09849-3}, keywords = {Biomarkers, Diabetes, Diabetic cardiomyopathy, Echocardiography, SGLT2 inhibitors}, journal = {Heart failure reviews}, doi = {10.1007/s10741-019-09849-3}, volume = {24}, issn = {1382-4147}, title = {Minireview: are SGLT2 inhibitors heart savers in diabetes?}, keyword = {Biomarkers, Diabetes, Diabetic cardiomyopathy, Echocardiography, SGLT2 inhibitors} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font